FAM
VRDN icon

Fred Alger Management’s Viridian Therapeutics VRDN Stock Holding History

Fred Alger Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,406
Closed -$1.07M – 515
2025
Q4 		$1.07M Buy
+34,406
New +$944K ﹤0.01% 355
2023
Q3 		– Sell
-107,318
Closed -$2.55M – 546
2023
Q2 		$2.55M Sell
107,318
-216,358
-67% -$5.55M 0.01% 313
2023
Q1 		$8.23M Sell
323,676
-104,597
-24% -$3.35M 0.04% 213
2022
Q4 		$12.5M Buy
428,273
+167,190
+64% +$3.85M 0.07% 192
2022
Q3 		$5.36M Buy
+261,083
New +$4.69M 0.03% 253

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fred Alger Management's VRDN Position: Q1 2026 in Review

Fred Alger Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 34,406 shares — an estimated $1.07M sold.

Fred Alger Management first reported a position in VRDN in Q3 2022 and held it in 5 quarters. The position peaked at $12.5M in Q4 2022. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Fred Alger Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fred Alger Management sold 34,406 Viridian Therapeutics shares in Q1 2026, an estimated $1.07M.
  • Fred Alger Management first reported a position in Viridian Therapeutics in Q3 2022 and held it in 5 quarters.
  • Fred Alger Management's Viridian Therapeutics position peaked at $12.5M in Q4 2022.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.